Group items tagged

The NHS catch up plan to bring down the number of waiters in the diagnostic list has helped in witnessing a drop of 6,500 people waiting more than two years for elective treatment between February and March. While those waiting more than 78 weeks - a year and a half - dropped by 5,700 over the same period. According to latest month data published today (May 12) more than two million diagnostic tests were carried out - the highest total for March on record - and an increase of 217,000 on the previous month (Feb 2022). The data revealed that it was also the highest month on record for cancer referrals, with 253,796 people checked in March alone - an almost 40 per cent increase on the number of checks made in March 2020. Alongside this, almost 30,000 people started treatment for cancer (28,378) - the second highest number on record. This is second only to March 2020, with 28,881 people starting treatment.

Leading pharmacy group Weldricks has strengthened its commitment to providing the highest quality of care to the communities it serves by implementing the RPS Daffodil Quality Improvement Standards for Community Pharmacy. The Royal Pharmaceutical Society (RPS) on Monday (20 November) announced that Weldricks will soon be rolling out the Daffodil Standards across half its stores in South Yorkshire. Developed in partnership with UK charity Marie Curie, the RPS Daffodil Standards serve as a framework for improving the quality of palliative and end-of-life care provided by community pharmacy teams. Amy Marlin, Superintendent Pharmacist of Weldricks, commented that the implementation of the RPS Daffodil Standards is "another step forward in our journey to provide the highest quality of care to the communities we serve."

A new study has revealed that public trust in services provided by local pharmacies ranks highest in the UK, although confidence in the NHS has nosedived following the pandemic. The 2022 Edelman Trust Barometer report published on Wednesday (April 21) found that around 78 per cent of respondents trust their local pharmacies, the highest for any provider cited in the survey. Besides, 72 per cent said pharmacists are among the most trusted to tell the truth about health matters and protect public health, almost similar to 'my doctor' (75%) and health experts (74%). Just under half of them said the pandemic has decreased their confidence that the NHS is well-equipped in handling major health crisis. The survey also revealed that 60 per cent think they lack access to high-quality healthcare.

Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.

Dispensing activity by community pharmacy in England has witnessed a 4.2 per cent increase across the year 2021 till March 2022, the Pharmacy Market Review 2022 report revealed. The report launched by Christie & Co, said: "All pharmacy settings saw improvements in dispensing numbers, with standard community settings seeing the highest increase of 4.2 per cent, with the average moving to 7,173 items, albeit still below the combined average." "The independent sector fared better than corporate pharmacy, with a combined average increase of 3.5 per cent versus a 1.8 per cent increase in corporate dispensing. Despite some improvement, integrated pharmacies remained the lowest at 1.9 per cent, in part due to the continued restrictions on patient access." Dispensing activity for England across the year to March 2022 increased by 4.5 per cent to an average of 7,765 items per month, reversing the decline witnessed in 2021.

Challenges in accessing the NHS waiting list are pushing more and more people toward private-funded alternatives for access, diagnosis and treatment, thereby increasing the demand for private health cover. According to a report published by health data provider LaingBuisson, the demand for private health cover, including medical and dental insurance and cash plans, has surged to its highest levels since 2008. The UK's overall health cover market reached £6.7 billion in 2022, an increase of £385 million from the previous year. During the period from 2020 to 2022, the market experienced annual growth rate of 6.1 per cent, a significant increase compared to the average annual growth rate of 1.7 per cent observed between 2008 and 2019, the research found. A total of 4.2 million people were subscribed to medical cover schemes in 2022. When dependents covered by these policies were included, the number reached 7.3 million - the highest count since 2008. LaingBuisson's analysis showed that medical cover volumes were steady through most of the 2010s, but began to increase alongside rises in the NHS waiting list from 2018.

Community pharmacies were responsible for dispensing over 99 per cent of items in 2022/23, revealed General Pharmaceutical Services for Northern Ireland, Annual Statistics 2022/23 published on Thursday (29 June). While the remaining one per cent dispensed by appliance contractors and dispensing doctors. According to the statistics, on average, each community pharmacy dispensed over 84,000 items in 2022/23, witnessing a growth of over 3 per cent on the previous year to 44.6 million in 2022/23, which is the highest level of dispensing recorded. This equated to BSO processing 2.1 million prescription forms per month, on average, throughout the year, representing a 4 per cent increase on the just over 2.0m processed each month last year. The total ingredient cost over the year was £486.9 million. This was an increase of approaching 7 per cent on the previous year, which was around double the percentage increase in the number of items dispensed. The annual ingredient cost total has fluctuated since the beginning of the series but was over 18 per cent higher in 2022/23 than in 2013/14.

Medical sector has the third highest number of businesses currently for sale, with hospitality and retail technology firms most likely to sell up next year, according to the UK Business Investment Report. There are 4,300 registered medical businesses in the UK, and approximately 355 (one in every 12.11) are currently up for sale. Topping the list was the hospitality sector with one in every 9.88 businesses up for sale, ahead of retail technology businesses (1 in 10.13). At the bottom of the table were owners of agriculture businesses with just one in every 943 businesses up for sale. Transportation and software/IT business owners followed in a similar manner with one in every 802 businesses being up for sale.

NHS England is encouraging people to get their flu and Covid vaccines as hospitals dealt with the highest number of norovirus and flu cases this winter. An average of 688 patients with norovirus were in hospital each day last week, 75 per cent higher than the same time last year (393), according to the latest data from NHS England. The data also showed an average of 2,226 patients with flu in hospital each day last week, which is three-quarters higher than the same week last January (1,290). Compared to last month, there has been an 80 per cent increase in the daily count of norovirus cases and 70 per cent in flu cases. In the week ending Dec 31, NHSE recorded 1,312 hospital admissions due to norovirus and 376 and 1,312 flu cases each day.

The Pharmacists' Defence Association (PDA) has issued an advisory information to community pharmacy contractors about Paxlovid antiviral treatment for non-hospitalised patients. "Patients will be assessed to see if they meet the criteria for inclusion and will need careful checking to see if Paxlovid therapy is safe due to the significant number of drug interactions. Assessment and prescribing are provided via dedicated services with dispensing and supply arranged by the central supply service or via participating community pharmacies," said the PDA. Every pharmacist can support this service by making themselves familiar with the service set up in their area. This is so that they can provide advice and signpost to healthcare colleagues and patients. Pharmacists working in general practice may also be able to help with identifying newly diagnosed highest risk patients. Whilst most of this group should have already been identified and contacted, no system is entirely foolproof. The PDA's advisory note provides information around indemnity and links to information about the prescribing and administration of Paxlovid since it is being provided under a temporary authorisation, and is subject to numerous drug-drug interactions, and is a recommended first-line treatment.

England won't have any new Covid-19 restrictions before the end of 2021, health secretary Sajid Javid said on Monday (December 27) whilst the government awaits more evidence on whether the NHS can cope with high infection rates in the new year. "There will be no further measures before the new year," Javid told reporters, adding: "When we get into the new year, of course we will see then whether we do need to take any further measures." He said that the highly transmissible Omicron variant of the virus now accounted for around 90 per cent of cases across England and urged people to celebrate New Year cautiously. The government's attention is focused on the number of patients being hospitalised with Omicron after early data last week suggested the variant carried a lower risk of admission. The latest data showed the number of patients in hospital in England with Covid-19 was its highest since March, at 8,474, but a long way off peaks above 34,000 in January. A combination of factors, including Britain's vaccination programme, the lag between infections and hospitalisations and the potentially less harmful effects of the Omicron variant have all been put forward by health experts as possible explanations for lower numbers.

In its first, the National Institute for Health and Care Excellence (NICE) has recommended the use of Pre Exposure Prophylaxis (PrEP) to treat people at the highest risk of catching HIV. The announcement comes along with a consultation on draft guideline by NICE on reducing sexually transmitted infections. NICE's recommendation is backed up by the government's HIV Action Plan to hit zero new transmissions of HIV by 2030. The pill prevents HIV by stopping the virus from crossing into the healthy cells and replicating. According to the UK PROUD study, PrEP reduced the risk of HIV infection by 86 per cent for men who have sex with men. However, people taking the pill must also get regular HIV testing and STI screening done every three months.

A news report suggests the Department of Health and Social Care is aiming to be ready to start charging for Covid-19 tests which are currently free at the end of June. Britain has been increasingly dependent on rapid testing to try to tackle the more-transmissible Omicron variant, which has spread rapidly through the population but is less severe. The government has previously said it will end the universal free provision of easy-to-use lateral flow devices (LFDs) at a "later stage", with individuals and businesses bearing the cost. The Department of Health has declined to say what the tests cost, citing commercial contracts. One source has told the Reuters news agency they can run to £30 for a pack of seven. Free pick up from pharmacies The tests have been made freely available to order online or pick up from local pharmacies since April. The UK Health Security Agency said that between December 30 and January 5 more than 8 million LFDs were conducted, the highest weekly figure on record.

A second Global Covid-19 Summit will be held virtually next month for countries to discuss efforts to end the pandemic and prepare for future health threats, according to a joint statement on Monday (April18). "The emergence and spread of new variants, like Omicron, have reinforced the need for a strategy aimed at controlling Covid-19 worldwide," the White House said in a news release with the Group of Seven and Group of 20 nations. The announcement comes amid a surge of Covid-19 cases around the world prompted by easily transmissible variants of the virus. China's most populous city, Shanghai, is trying to return to normal after a nearly three-week shutdown, which, along with wider China curbs, are taking a toll on the world's No. 2 economy. The summit will build on efforts and commitments made at the first global summit in September, including getting more people vaccinated, sending tests and treatments to highest-risk populations, expanding protections to health care workers and generating financing for pandemic preparedness, the statement said.

Hundreds of workers at pharmaceutical giant GlaxoSmithKline are set to strike over a "derisory" pay offer way below the level of British inflation, a union said on Wednesday (April 20). Unite general secretary Sharon Graham accused GSK of "colossal corporate greed" over an effective pay cut in real terms as Britain experiences its highest inflation in 30 years. GSK said it was "disappointed that the Unite union has taken the decision to strike", adding that the British group "remains committed to… a solution". It said in a statement: "We recognise the impact inflation rates are having on people around the country and are strongly committed to supporting the skilled people who work in GSK manufacturing." About 500 Unite members, or around 13 per cent of GSK's UK manufacturing workforce, voted to strike, the drugs group said. GSK said it had offered a four-percent increase in base salary plus one-off awards.

The General Pharmaceutical Council is appointing a new Chief Pharmacy Officer to strengthen the professional voice within the senior leadership team. This introduction is aimed at fostering a culture of enterprise leadership, inclusion and collaboration within the organisation, GPhC said in a statement. According to GPhC, the Chief Pharmacy Officer will serve as the authoritative representative of the pharmacy regulator in public, within the pharmacy professions, and increasingly in multi-disciplinary teams and collaborative regulatory work. "They will act as the executive lead on pharmacy inspection and regulatory insight, providing professional leadership within the GPhC and collaborating closely with pharmacist and pharmacy technician colleagues across the organisation." The Chief Pharmacy Officer, reporting to the Chief Executive and Registrar, will hold the highest professional position within the GPhC executive, providing pharmacy leadership across the organisation, GPhC said.

The kidney transplant surgery cost in India is significantly lower compared to Western countries, while still maintaining one of the highest success rates globally.

Kailash Deepak Hospital is your top choice for dental care excellence in Delhi. Our expert dentists provide the highest quality dental services, including dental implants. Trust us for your dental health needs in the heart of Delhi.

Atorvastatin, a medicine to treat high blood cholesterol, is the most dispensed drug with 59 million items in England in 2022/23, revealed the NHS Business Services Authority (NHSBSA) on Thursday (8 June). While Apixaban (an anticoagulant) was the drug with the highest costs of £430 million. Apixaban 5mg tablets had the largest increase in cost between 2021/22 and 2022/23 in England, with an increase of £280 million. NHSBSA's annual statistics report 'Prescription Cost Analysis-England 2022/23' published also has revealed an eight per cent rise in the prescription items that were dispensed in the community in England. The report highlighted that in 2022/23, 1.18 billion prescription items were dispensed at a cost of £10.4 billion in the community in England, witnessing an increase of eight per cent from £9.69 billion in 2021/22.

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority's (CMA) findings against two pharmaceutical manufacturers who consistently overcharged hydrocortisone tablets for over a decade. Auden/Actavis UK's pricing for the critical medicine 'hydrocortisone' from 2008 to 2018 constituted an abuse of their dominant market position, leading to fines nearing £130 million, CMA said in a statement. "These companies increased the price of this crucial medicine by over 10,000 per cent, soaring from 70p to £72 within that period. These are the highest ever CMA penalties upheld by the Tribunal," the CMA said. In July 2021, the CMA imposed fines exceeding £265 million on hydrocortisone manufacturers Auden Mckenzie and Actavis UK, which acquired Auden's business in 2015 and subsequently became Accord-UK. The fines were imposed for abuse of dominance and collusion by both the parent companies and potential competitors. The recent verdict, announced on September 18, comes five weeks after the Tribunal supported the CMA's decision in a separate case regarding the pricing of medicines supplied to the NHS. In that prior case, fines amounted to £84 million.